The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Complement function in mAb-mediated cancer immunotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“Similarly, the tumor regression activity of a chimeric anti-CD20 mAb (Rituximab) was significantly reduced in FcgR deficient mice as compared to wild-type mice [10, 11 ].”
BackgroundCartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.-M., Bernasconi, S., Tedesco, F., Rambaldi, A., & Introna, M. (2000) · Blood · doi:10.1182/blood.v95.12.3900 · Cited by 604
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Vetvicka, V, Thornton, B. P., & Ross, G. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118777 · Cited by 407
Self-citationFishelson, Z. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00112-3 · Cited by 400
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
Fedarko, N. S., Jain, A., Karadağ, A., Eman, M. R. V., & Fisher, L. W. (2001) · PubMed · Cited by 380
DIVERGENT ROLES FOR F c RECEPTORS AND COMPLEMENT IN VIVO
Ravetch, J. V., & Clynes, R. A. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.421 · Cited by 366
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Xia, Y., Vetvicka, V., Yan, J., Hanikýřová, M., Mayadas, T. N., & Ross, G. D. (1999) · PubMed · Cited by 265
Self-citationThe mechanisms of action of rituximab in the elimination of tumor cells
Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247
Xia, Y., Větvička, V., Yan, J., Hanikýřová, M., Mayadas, T., & Ross, G. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2281 · Cited by 244
Self-citationRegulation of the Adhesion versus Cytotoxic Functions of the Mac-1/CR3/αMβ2 - lntegrin Glycoprotein
Ross, G. D. (2000) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v20.i3.20 · Cited by 217
Self-citationFedarko, N. S., Fohr, B., Robey, P. G., Young, M. F., & Fisher, L. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001123200 · Cited by 213
Immune evasion of tumor cells using membrane-bound complement regulatory proteins
Gorter, A., & Meri, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01537-6 · Cited by 206
Self-citationOrally administered β-glucans enhance anti-tumor effects of monoclonal antibodies
Cheung, N.-K. V., Modak, S., Vickers, A., & Knuckles, B. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-002-0321-3 · Cited by 180
Bannerji, R., Kitada, S., Flinn, I. W., Pearson, M., Young, D., Reed, J. C., & Byrd, J. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.012 · Cited by 178
Hong, F., Hansen, R., Yan, J., Allendorf, D. J., Baran, J., Ostroff, G. R., & Ross, G. D. (2003) · PubMed · Cited by 165
Self-citationSpiridon, C., Ghetie, M.-A., Uhr, J. W., Marcheş, R., Li, J. L., Shen, G. L., & Vitetta, E. S. (2002) · PubMed · Cited by 157
Yan, J., Větvička, V., Xia, Y., Coxon, A., Carroll, M. C., Mayadas, T. N., & Ross, G. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.6.3045 · Cited by 149
Self-citationKennedy, A. D., Solga, M. D., Schuman, T. A., Chi, A. W., Lindorfer, M. A., Sutherland, W. M., Foley, P. L., & Taylor, R. P. (2003) · Blood · doi:10.1182/blood-2002-03-0876 · Cited by 141
Yan, J., Větvička, V., Xia, Y., et al. (1999) · PubMed · Cited by 140
Muc-1 Core Protein Is Expressed on Multiple Myeloma Cells and Is Induced by Dexamethasone
Treon, S. P., Mollick, J. A., Urashima, M., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1287 · Cited by 125
Shin, M. L., Hänsch, G. M., Hu, V. W., & Nicholson-Weller, A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.5.1777 · Cited by 92
Cheung, N. V., & Modak, S. I. (2002) · PubMed · Cited by 92
Monoclonal antibodies as therapeutics in oncology
Trikha, M., Li, Y., & Nakada, M. T. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00348-8 · Cited by 83
Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma
Ellis, J. H., Barber, K. A., Tutt, A. N. J., Hale, C., Lewis, A., Glennie, M. J., Stevenson, G. T., & Crowe, J. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.2.925 · Cited by 81
Harris, C. L., Spiller, O. B., & Morgan, B. P. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00066.x · Cited by 80
Chen, S., Caragine, T. A., Cheung, N. V., & Tomlinson, S. (2000) · PubMed · Cited by 65
Self-citationBlok, V. T., Daha, M. R., Tijsma, O., Harris, C. L., Morgan, B. P., Fleuren, G. J., & Gorter, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3437 · Cited by 52
Self-citationAndoh, A., Fujiyama, Y., Sumiyoshi, K., Sakumoto, H., & Bamba, T. (1996) · Gastroenterology · doi:10.1016/s0016-5085(96)70058-6 · Cited by 52
Reiter, Y., & Fishelson, Z. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.8.2771 · Cited by 43
Caragine, T. A., Okada, N., Frey, A. B., & Tomlinson, S. (2002) · PubMed · Cited by 27
Self-citation
Cited by
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Modulation of the antitumor immune response by complement
Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D. (2008) · Nature Immunology · doi:10.1038/ni.1655 · Cited by 778
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Metadata
- Authors
- Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 25
- Issue
- 3
- Pages
- 158-164
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2010690729
- Cited by
- 262
- References
- 38
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.